Literature DB >> 1748828

Glucose-dependent effects of pancreastatin on insulin and glucagon release.

J von Schönfeld1, J Kleimann, M K Müller, M Rünzi, H Goebell.   

Abstract

Pancreastatin (PST), a peptide isolated from porcine pancreas in 1986, has been reported to inhibit insulin and to stimulate glucagon secretion. Since both of these effects have been questioned, we investigated the effect of PST (20, 200, or 2000 pM) on hormone release in the isolated perfused rat pancreas at different glucose levels (1.7, 5.5, 11.1, and 16.7 mM). At 1.7 mM glucose, 20 pM PST had no significant effect on glucagon secretion, whereas 200 pM and 2 nM PST significantly inhibited glucagon release. At a concentration of 5.5 mM glucose, insulin output was not affected by PST in any of the concentrations tested. At 11.1 mM glucose, however, 200 pM and 2 nM PST significantly inhibited insulin output. At 16.7 mM glucose, insulin secretion was significantly reduced by all concentrations of PST tested. Unstimulated exocrine pancreatic secretion was not affected by PST in any of the experimental settings. We conclude that PST inhibits glucagon and insulin secretion dose-dependently, and these effects apparently are glucose-dependent. PST does not influence basal exocrine pancreatic secretion in vitro.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748828     DOI: 10.1007/bf02924117

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  21 in total

1.  Pancreastatin inhibits insulin secretion as induced by glucagon, vasoactive intestinal peptide, gastric inhibitory peptide, and 8-cholecystokinin in the perfused rat pancreas.

Authors:  E Peiró; P Miralles; R A Silvestre; M L Villanueva; J Marco
Journal:  Metabolism       Date:  1989-07       Impact factor: 8.694

2.  Pancreastatin inhibits insulin release from Rin m 5F cells: reversion by pertussis toxin.

Authors:  A M Lorinet; K Tatemoto; M Laburthe; B Amiranoff
Journal:  Eur J Pharmacol       Date:  1989-02-07       Impact factor: 4.432

3.  Differential sensitivity of rat exocrine and endocrine pancreas to cyclosporine.

Authors:  M K Müller; K Bergmann; H Degenhardt; G Klöppel; M Löhr; H J Coone; H Goebell
Journal:  Transplantation       Date:  1988-04       Impact factor: 4.939

4.  Galanin and pancreastatin inhibit stimulated insulin secretion in the mouse: comparison of effects.

Authors:  S Lindskog; B Ahrén
Journal:  Horm Res       Date:  1988

5.  Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion.

Authors:  K Tatemoto; S Efendić; V Mutt; G Makk; G J Feistner; J D Barchas
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

6.  Bioactivity of synthetic human pancreastatin on exocrine pancreas.

Authors:  A Funakoshi; K Miyasaka; R Nakamura; K Kitani; S Funakoshi; H Tamamura; N Fujii; H Yajima
Journal:  Biochem Biophys Res Commun       Date:  1988-11-15       Impact factor: 3.575

7.  The sequence of porcine chromogranin A messenger RNA demonstrates chromogranin A can serve as the precursor for the biologically active hormone, pancreastatin.

Authors:  A L Iacangelo; R Fischer-Colbrie; K J Koller; M J Brownstein; L E Eiden
Journal:  Endocrinology       Date:  1988-05       Impact factor: 4.736

8.  Localization of pancreastatin immunoreactivity in porcine endocrine cells.

Authors:  M Ravazzola; S Efendic; C G Ostenson; K Tatemoto; J C Hutton; L Orci
Journal:  Endocrinology       Date:  1988-07       Impact factor: 4.736

9.  Comparative effects of mammalian pancreastatins on the pancreatic exocrine secretion.

Authors:  A Funakoshi; K Miyasaka; K Kitani; S Funakoshi; H Tamamura; N Fujii; I Nakano; K Tatemoto
Journal:  Jpn J Physiol       Date:  1989

10.  Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  A Funakoshi; K Tateishi; H Shinozaki; M Matsumoto; H Wakasugi
Journal:  Regul Pept       Date:  1990-09-10
View more
  2 in total

Review 1.  Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity.

Authors:  Gautam K Bandyopadhyay; Sushil K Mahata
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-08       Impact factor: 5.555

Review 2.  Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.

Authors:  Sushil K Mahata; Angelo Corti
Journal:  Ann N Y Acad Sci       Date:  2019-10-06       Impact factor: 5.691

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.